Urocortin-III
An endogenous CRF2-selective peptide studied for vascular, cardiac, metabolic and stress-related physiology.
- Human evidencen/a
- Animal evidencen/a
- Mechanisticn/a
- Safety knowledgen/a
- Editorial confidence4/5
Evidence Snapshot
- Overall
- 3/5Moderate certainty (with caveats)
- Human
- 3/5Multiple human studies
- Animal
- 0/5None identified
- In-vitro
- 0/5None identified
- Safety
- 2/5Partially characterised safety
Scientific identity
- Peptide family
- Corticotropin-releasing factor family
- Entity class
- Endogenous neuropeptide
- Alternative names
- Urocortin-3UCN3Stresscopin
Identified as a CRF2-selective urocortin-family peptide, also called stresscopin.
Proposed Mechanisms
- not-yet-documentedpending-editorial-review
- Corticotropin-releasing factor type 2 receptor signalling →strong
- Nitric oxide / blood flow →supported
Reported / Studied Uses
- Weight managementEvidence · insufficient
Human Evidence
Small human vascular and cardiovascular studies show prolonged vasodilation and acute haemodynamic activity.
Animal Evidence
Preclinical studies explore cardiovascular, metabolic and pancreatic actions.
Safety & Unknowns
Regulatory Status
| Country | Status | Notes |
|---|
Community Observations
References
- No verified references linked yet. Editors will add primary sources.
Full Disclaimer
This page is for educational information only. It does not constitute medical advice, diagnosis, treatment, dosing guidance, or a recommendation to use any peptide, medicine or research chemical. Many peptides discussed on Atlas are not approved for human use in most jurisdictions and may have limited or unknown long-term safety data.
Community observations shown on this page are anonymised, moderated and observational only. They do not establish safety or effectiveness.
Always consult a qualified healthcare professional before making decisions about your health. See medical disclaimer and methodology.